Engaging clinical champi[INVESTIGATOR_902657]# 05736718  
Version date: 3/15/2023  
 
 
  
Analysis plan for HPV vaccine champi[INVESTIGATOR_902658]-inferiority trial is to compare Champi[INVESTIGATOR_902659] (AAT)  to Traditional AAT  on HPV vaccine initiation  among patients ages [ADDRESS_1266025] as effective as Traditional AAT for increasing HPV vaccine uptake.   
 
Design  & Power  
We will randomize 40 clinics within multiple healthcare systems to the two trial arms  (Champi[INVESTIGATOR_902660]) . To maximize balance in trial arms, we block randomization by [CONTACT_902665] a 1:[ADDRESS_1266026] â‰¥80% power to conclude non -inferiority of Champi[INVESTIGATOR_902661] â‰¥8% points over the secular trend. 
This calculation assumes: 1) a clinic -level ICC of .033 for change in HPV vaccine initiation, as observed in 
our pi[INVESTIGATOR_20732]; 2) a non -inferiority margin of .04; 3) 100 patients, ages 9 -12, per clinic on average; 4) a 
secular trend of 10% points; and 5) Traditional AAT effect of 5% points, as observed in our prior trial.[ADDRESS_1266027] size of â‰¥8% points with Champi[INVESTIGATOR_902662], given that we are modeling HPV 
vaccination amon g unvaccinated adolescents, whose uptake will be higher proportionally than the 
general population.  
 
The non -inferiority margin, delta, will be .04, which we have selected to detect any clinically meaningful 
difference between the effectiveness of our interventions.  To test for non -inferiority with a margin of 
.04, we will translate the lower and upper 95% confidence interval limits into predicted probability units 
and conclude that Champi[INVESTIGATOR_902663] .04.   
 
Analy tic Plan  
Primary trial outcome: HPV vaccine initiation by 12 -month follow -up  
We will assess the vaccination status of adolescents who are HPV vaccine naÃ¯ve at baseline, using 
routinely collected EHR data from our healthcare systems  and submitted to the Wisconsin Collaborative 
for Healthcare Quality .  
 
We will model HPV vaccine initiation  using a generalized estimating equation (GEE) for logistic 
outcomes. GEE models accommodate non -independence due to nesting of patients within clinics by 
[CONTACT_902666]. The outcome of the model will be patient -level HPV vaccine initiation  at 
follow -up (0=no, 1=yes):  
ğ‘™ğ‘™ğ‘™ğ‘™(ğ‘ğ‘(ğ‘£ğ‘£ğ‘£ğ‘£ğ‘¥ğ‘¥2ğ‘–ğ‘–ğ‘–ğ‘–)
1âˆ’ğ‘ğ‘(ğ‘£ğ‘£ğ‘£ğ‘£ğ‘¥ğ‘¥2ğ‘–ğ‘–ğ‘–ğ‘–))=ğ‘ğ‘0+ğ‘ğ‘1ğ¶ğ¶â„ğ‘£ğ‘£ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘™ğ‘™ğ‘–ğ‘–+ğ‘ğ‘2ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘ğ‘ğ‘–ğ‘– 
Trial arm will be the primary fixed effect as a two -level, categorical variable (Champi[INVESTIGATOR_902664]. 
Traditional AAT). Since we will be block random izing on healthcare system, system membership will be 
added as a n n-level, categorical covariate  where n is the number of participating systems . Tests will be 
2-tailed with Î±=.05   Statistical analyses will be conducted in SAS 9.4 (Cary, NC) and R 4.2.2.  
 
Missing Data  
We will use all available data in computing the primary outcome of HPV vaccine initiation by 12 -month 
follow -up as per our intent -to-treat protocol. We will drop the clinic  if no data are available  (e.g., due to 
clinic closure).  
 
Adjustment for  covariates  
We do n ot plan to adjust for demographic or other baseline characteristics p er CONSORT  
recommendations ( Consort , 2010 ). 
 
Secondary trial outcome  
The s econdary  trail outcome is  HPV vaccination  series completion (2 doses) at 12 months, which we will 
evaluate in the same manner as the primary outcome.   
 